Breast Cancer Cell Density: Imaging assay of the density- and context-dependence of small molecule perturbagen response in breast cancer cell lines. Dataset 1 of 3: Cell count and normalized growth rate inhibition values. - Dataset (ID:20256)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Replicate | Seeding Density | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|
SK-BR-3 | Linsitinib | 0.01 | uM | 8 | 156.25 | 36.27 | 141.00 | 126.50 | 1.1146 | 1.1241 |
SK-BR-3 | Linsitinib | 0.031623 | uM | 8 | 156.25 | 36.27 | 176.00 | 126.50 | 1.3913 | 1.4022 |
SK-BR-3 | Lapatinib | 0.01 | uM | 8 | 156.25 | 36.27 | 190.00 | 126.50 | 1.5020 | 1.5064 |
SK-BR-3 | 17-AAG | 0.031623 | uM | 8 | 156.25 | 36.27 | 75.00 | 126.50 | 0.5929 | 0.4964 |
SK-BR-3 | Lapatinib | 0.1 | uM | 8 | 156.25 | 36.27 | 107.00 | 126.50 | 0.8459 | 0.8226 |
SK-BR-3 | Erlotinib | 0.31623 | uM | 8 | 156.25 | 36.27 | 205.00 | 126.50 | 1.6206 | 1.6144 |
SK-BR-3 | Linsitinib | 0.31623 | uM | 8 | 156.25 | 36.27 | 95.00 | 126.50 | 0.7510 | 0.7062 |
SK-BR-3 | Lapatinib | 0.0016596 | uM | 8 | 156.25 | 36.27 | 130.00 | 126.50 | 1.0277 | 1.0305 |
SK-BR-3 | 17-AAG | 0.01 | uM | 8 | 156.25 | 36.27 | 89.00 | 126.50 | 0.7036 | 0.6455 |
SK-BR-3 | Lapatinib | 0.031623 | uM | 8 | 156.25 | 36.27 | 105.00 | 126.50 | 0.8300 | 0.8036 |
SK-BR-3 | Lapatinib | 0.0033113 | uM | 8 | 156.25 | 36.27 | 118.00 | 126.50 | 0.9328 | 0.9243 |
SK-BR-3 | 17-AAG | 0.1 | uM | 8 | 156.25 | 36.27 | 73.00 | 126.50 | 0.5771 | 0.4742 |
SK-BR-3 | Linsitinib | 0.0033113 | uM | 8 | 156.25 | 36.27 | 102.00 | 126.50 | 0.8063 | 0.7748 |
SK-BR-3 | Linsitinib | 3.1623 | uM | 8 | 156.25 | 36.27 | 139.00 | 126.50 | 1.0988 | 1.1074 |
SK-BR-3 | Erlotinib | 0.0033113 | uM | 8 | 156.25 | 36.27 | 156.00 | 126.50 | 1.2332 | 1.2467 |
SK-BR-3 | Lapatinib | 1 | uM | 8 | 156.25 | 36.27 | 89.00 | 126.50 | 0.7036 | 0.6455 |
SK-BR-3 | 0 | uM | 8 | 156.25 | 36.27 | 100.00 | 126.50 | 0.7905 | 0.7554 | |
SK-BR-3 | 0 | uM | 8 | 156.25 | 36.27 | 74.00 | 126.50 | 0.5850 | 0.4853 | |
SK-BR-3 | 0 | uM | 8 | 312.50 | 180.33 | 293.00 | 276.75 | 1.0587 | 1.1935 | |
SK-BR-3 | 0 | uM | 8 | 312.50 | 180.33 | 246.00 | 276.75 | 0.8889 | 0.6529 | |
SK-BR-3 | Linsitinib | 0.1 | uM | 8 | 312.50 | 180.33 | 293.00 | 276.75 | 1.0587 | 1.1935 |
SK-BR-3 | Lapatinib | 3.1623 | uM | 8 | 312.50 | 180.33 | 166.00 | 276.75 | 0.5998 | -0.1254 |
SK-BR-3 | Linsitinib | 10 | uM | 8 | 312.50 | 180.33 | 175.00 | 276.75 | 0.6323 | -0.0474 |
SK-BR-3 | Erlotinib | 0.1 | uM | 8 | 312.50 | 180.33 | 385.00 | 276.75 | 1.3911 | 2.4124 |
SK-BR-3 | Erlotinib | 19.9526 | uM | 8 | 312.50 | 180.33 | 245.00 | 276.75 | 0.8853 | 0.6420 |